Aerovate Therapeutics Inc
NASDAQ:AVTE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Aerovate Therapeutics Inc
NASDAQ:AVTE
|
US |
|
S
|
SICHUAN HEXIE SHUANGMA Co Ltd
SZSE:000935
|
CN |
|
T
|
Tomei Consolidated Bhd
KLSE:TOMEI
|
MY |
|
Sumedha Fiscal Services Ltd
BSE:530419
|
IN |
|
UEX Ltd
TSE:9888
|
JP |
|
Progyny Inc
NASDAQ:PGNY
|
US |
|
C
|
CG Oncology Inc
NASDAQ:CGON
|
US |
|
H
|
Hup Seng Industries Bhd
KLSE:HUPSENG
|
MY |
|
Savor Ltd
NZX:SVR
|
NZ |
|
I
|
Immofinanz AG
WSE:IIA
|
AT |
|
Dorel Industries Inc
TSX:DII.B
|
CA |
|
S
|
Sandoz Group AG
SIX:SDZ
|
CH |
Aerovate Therapeutics Inc
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.
